Page last updated: 2024-09-04

docetaxel anhydrous and Adenocarcinoma, Endometrioid

docetaxel anhydrous has been researched along with Adenocarcinoma, Endometrioid in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (33.33)	29.6817
2010's	4 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cao, X; Feng, Y; Huang, H; Huang, X; Huang, Y; Lan, C; Liu, J	1
Anan, H; Fukagawa, S; Katsuta, T; Kiyoshima, C; Maehara, M; Miyahara, D; Miyamoto, S; Miyata, K; Takahashi, Y; Yotsumoto, F	1
Leminen, A; Mäenpää, J	1
Bottsford-Miller, J; Broaddus, RR; Bruckheimer, E; Coffey, D; Coffman, K; Coleman, RL; Gershenson, DM; Han, LY; Hwang, JY; Kamat, AA; Landen, CN; Lin, YG; Lu, C; Merritt, WM; Nick, AM; Nugent, E; Sood, AK; Spannuth, WA; Stone, RL	1
Argenta, PA; Boente, MP; Carson, LF; Downs, LS; Dusenbery, K; Geller, MA; Ghebre, R; Ivy, JJ; Jonson, AL; Judson, PL; Vogel, RI	1
Adachi, S; Iijima, T; Ito, K; Kimura, T; Nakatsuji, Y; Nobunaga, T	1

Trials

2 trial(s) available for docetaxel anhydrous and Adenocarcinoma, Endometrioid

Article	Year
Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:2 Topics: Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Survival Rate; Taxoids; Treatment Outcome	2009
A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecologic oncology, 2011, Volume: 121, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; Young Adult	2011

Article

Year

Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study.

Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:2

Topics: Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Survival Rate; Taxoids; Treatment Outcome

2009

A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.

Gynecologic oncology, 2011, Volume: 121, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; Young Adult

2011

Other Studies

4 other study(ies) available for docetaxel anhydrous and Adenocarcinoma, Endometrioid

Article	Year
Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Time Factors; Treatment Outcome; Young Adult	2013
Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer. Anticancer research, 2016, Volume: 36, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk; Taxoids; Treatment Outcome	2016
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer biology & therapy, 2010, Dec-15, Volume: 10, Issue:12 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Endometrioid; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Endometrial Neoplasms; Female; Gene Expression; Humans; Ki-67 Antigen; Mice; Microvessels; Molecular Targeted Therapy; Neovascularization, Pathologic; Phosphorylation; Prognosis; Receptor Protein-Tyrosine Kinases; Receptor, EphA2; Receptors, Estrogen; Receptors, Progesterone; Survival; Taxoids; Vascular Endothelial Growth Factor A	2010
[Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Taxoids	2003